PMI Launches 'IQOS ILUMA i' in Czech Republic to Expand Smoke-Free Product Market Share

Nov.07.2024
PMI Launches 'IQOS ILUMA i' in Czech Republic to Expand Smoke-Free Product Market Share
PMI has launched its HTP device "IQOS ILUMA i" in the Czech market, highlighting its commitment to a smoke-free future.

According to a report by Metro.CZ, Philip Morris International (PMI) has launched its heated tobacco device "IQOS ILUMA i" in the Czech market.

 

The Chairman and CEO of the company, Fabio Costa, stated that...

 

We aim to continually provide consumers with innovative, cutting-edge solutions to offer them a scientifically based, superior choice. Our significant investments in research and development demonstrate our commitment to achieving a smoke-free future. I am thrilled to introduce today to our customers the 'IQOS ILUMA i' with various enhanced features.

 

It is reported that currently, PMI's smoke-free products account for over 50% of the total revenue in 25 markets, including the Czech Republic.

 

Oggie Kapetanovic, the category manager responsible for PMI's heated tobacco products, stated that: "Based on consumer demand and feedback, we have developed eight generations of IQOS devices in the past few years. We aim to achieve a fundamental transformation of our business in a more sustainable and responsible manner. This strategy has paid off for us. For example, in Czech Republic, over 500,000 adult smokers have already switched to using IQOS."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore will maintain etomidate’s classification under drug control laws while preparing new legislation targeting e-vaporisers, as authorities reinforce a hardline regulatory stance on vaping.
Feb.05
KT&G Q4 and Full-Year 2025 Results: Global CC Strongest, NGP Penetration Expands
KT&G Q4 and Full-Year 2025 Results: Global CC Strongest, NGP Penetration Expands
According to KT&G’s official website (Feb 5, 2026), KT&G released its 2025 fourth-quarter and full-year results. Driven by strong growth in its overseas cigarette business and a rebound in its real estate business, the company posted double-digit increases in both revenue and operating profit, reaching record-high performance.
Feb.05 by 2FIRSTS.ai
Charlie’s Holdings Signs Licensing Agreement with IKE Tech to Commercialize Age-Gated Vape Technology in the U.S.
Charlie’s Holdings Signs Licensing Agreement with IKE Tech to Commercialize Age-Gated Vape Technology in the U.S.
Charlie’s Holdings has signed a licensing agreement with IKE Tech to commercialize an age-gated vape activation system in the U.S. The technology combines biometric authentication, BLE hardware, and a mobile app for continuous device-level age verification. The company plans to test-market the system with SBX nicotine analogue products this spring and may later apply it to PACHA-branded ENDS.
News
Jan.06
JT Delivers Record FY2025 Results as RRP Accelerates and Ploom Expands Globally
JT Delivers Record FY2025 Results as RRP Accelerates and Ploom Expands Globally
JT reported record FY2025 revenue and adjusted operating profit, supported by combustible resilience and accelerating reduced-risk product growth. Heated tobacco volumes surged, led by Ploom. The group confirmed a major three-year RRP investment plan and projected further growth in 2026.
Feb.12
Russia’s Public Chamber official opposes “generational ban” on tobacco sales, citing rights concerns
Russia’s Public Chamber official opposes “generational ban” on tobacco sales, citing rights concerns
Vladislav Grib, deputy secretary of the Public Chamber of the Russian Federation, said a “generational ban” on cigarette sales—restricting sales based on year of birth—would not resolve smoking and would instead lead to human rights violations. He argued older cohorts would buy and share, and the approach would split citizens into two categories.
Jan.08 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11